GT
AVTX icon

Glenmede Trust’s Avalo Therapeutics AVTX Stock Holding History

Glenmede Trust’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$523K Buy
28,280
+2,550
+10% +$40.3K ﹤0.01% 967
2026
Q1 		$384K Buy
25,730
+5,280
+26% +$82.6K ﹤0.01% 1059
2025
Q4 		$371K Buy
+20,450
New +$345K ﹤0.01% 1051

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Glenmede Trust's AVTX Position: Q2 2026 in Review

Glenmede Trust increased its Avalo Therapeutics (AVTX) stake by 9.9% in Q2 2026, buying an estimated $40.3K and bringing the position to 28,280 shares worth $523K. The position accounts for ﹤0.01% of the portfolio, ranked #967.

Glenmede Trust first reported a position in AVTX in Q4 2025 and has held it in 3 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Glenmede Trust held 28,280 shares of Avalo Therapeutics worth $523K as of Q2 2026.
  • Glenmede Trust bought 2,550 Avalo Therapeutics shares in Q2 2026, an estimated $40.3K.
  • Avalo Therapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #967 holding.
  • Glenmede Trust first reported a position in Avalo Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.